Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + ivonescimab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-A1811 + ivonescimab is a combination therapy being investigated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 abnormalities, such as amplification or overexpression. SHR-A1811 is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) developed by Jiangsu Hengrui Pharmaceuticals, consisting of a trastuzumab-like antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker. Ivonescimab (AK112), developed by Akeso, is a first-in-class bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). This combination aims to provide a synergistic therapeutic effect by combining the direct cytotoxic cell killing of the ADC with the dual immune checkpoint blockade and anti-angiogenic properties of the bispecific antibody.
- Other names
- SHR-A1811 + AK112SHR-A1811 plus ivonescimabSHR-A-1811 plus ivonescimabSHR-A 1811 plus ivonescimabSHR-A1811 and AK112SHR-A-1811 and AK112SHR-A 1811 and AK112
02
Targets
TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SHR-A1811 + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + ivonescimab.